Anti-Transferrin Receptor Oligonucleotide Conjugates for PLN Knockdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiomyopathies caused by phospholamban (PLN) mutations, such as R14del, are ineffective, and there is a need for targeted therapeutics to address genetic abnormalities in PLN that lead to cardiac diseases like arrhythmogenic and dilated cardiomyopathy.
Innovation Solution
Development of antibody-oligonucleotide conjugates (AOC) that target PLN mRNA, specifically designed to inhibit PLN expression in cardiac muscle cells, using modified polynucleotides like antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to modulate PLN mRNA expression and reduce the toxic effects of mutant PLN proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional anti-arrhythmic and heart failure medications are used, then general cardiac symptoms may be alleviated, but they are ineffective for cardiomyopathies caused by specific PLN genetic mutations
Solution Approach 1:
The patent applies local quality by designing siRNA sequences that specifically target the mutated region of PLN mRNA (e.g., R14del mutation) rather than the entire PLN gene. This localized targeting approach allows the therapy to specifically address the pathological mutant allele while preserving wild-type PLN expression, thereby achieving both treatment effectiveness and selective adaptability for mutation-specific cardiomyopathies.
Solution Approach 2:
The patent utilizes parameter changes by modifying the siRNA sequence parameters to match specific PLN mutations. By changing the target sequence parameters of the siRNA to complement the mutated mRNA region, the therapy achieves high reliability in treating specific genetic variants while maintaining the ability to adapt to different mutation types through sequence customization.
2Reliability
If RNA interference is used to suppress PLN expression, then calcium cycling can be restored and cardiac function improved, but delivery to cardiac tissue must be achieved
Solution Approach 1:
The patent employs an intermediary approach by using modified nucleic acid sequences (such as 2'-O-methyl and phosphorothioate modifications) as mediators to facilitate delivery of the siRNA to cardiac tissue. These modifications act as intermediaries that protect the siRNA from degradation, enhance cellular uptake, and improve tissue penetration, thereby enabling reliable delivery while simplifying the overall administration process.
3Manufacturing precision
If allele-specific siRNA is designed to target mutant PLN, then selective knockdown of mutant transcript can be achieved, but sequence design complexity increases
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting only the specific mutated region of the PLN mRNA (e.g., the R14del mutation site) using carefully designed siRNA sequences. By extracting and focusing on the precise mutation site rather than the entire gene sequence, the patent achieves high manufacturing precision in allele-specific knockdown while actually reducing sequence design complexity through targeted rather than comprehensive sequencing approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AOCs effectively reduce PLN mRNA expression in cardiac muscle cells, thereby improving cardiac function and potentially preventing the progression of cardiomyopathies by restoring calcium homeostasis and reducing the need for cardiac transplantation.
Implementation Method 1
An anti-transferrin receptor antibody or antigen-binding fragment thereof is conjugated to a polynucleotide
Implementation Method 2
a polynucleotide that hybridizes to a target sequence of phospholamban (PLN) mRNA and mediates RNA interference against the PLN mRNA in a cardiac muscle cell
Data Source
AI summary
Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods of use for antibody-PLN targeting oligonucleotide conjugates (AOC).